Clinical studies show that increasing FGF-23, consistently and independent of traditional risk factors, is associated with increased risks of arterial stiffness, left ventricular hypertrophy, heart failure, myocardial infarction, stroke and cardiovascular mortality across a wide range of levels of kidney function [23, 25, 28]. The gene discussed is FGF23; the disease is Stroke.